Browse the evidence

Distributing protein intake evenly across meals (rather than concentrating it in lunch and dinner) is associated with better adherence to Recommended Nutrient Intake (RNI) standards, particularly in older adults, though current Korean dietary patterns show a significant skew toward evening consumption.

If you are an adult, check if you are eating most of your protein at lunch and dinner. Try to shift some of that protein to breakfast. Older adults (65+) are particularly likely to miss their protein targets because they skip breakfast; adding a protein source to your morning meal can significantly improve your chances of meeting daily health guidelines.

Older adults (65+) in Korea have significantly lower protein adequacy rates (35.7-51.9%) compared to younger adults (62.9-67.4%), primarily driven by lower total intake and a shift in protein sources from animal to plant (grains) at all meals.

Do not rely on national average protein statistics to judge your personal diet. If you are over 65, you are statistically likely to be under-consuming protein. Focus on increasing total grams per day, specifically by prioritizing animal proteins (meat, fish, dairy) over grains, which are the primary source for many elderly Koreans.

HDL functionality (cholesterol efflux capacity) and proteomic composition are better predictors of CVD risk than static HDL cholesterol levels, and these functional properties are negatively impacted by SFA-enriched diets compared to MUFA-enriched diets.

Don't just focus on raising your HDL number. Focus on eating healthy fats (like MUFA) rather than excessive saturated fats, as this may improve the *function* of your HDL (how well it clears cholesterol) and reduce inflammation. This is an emerging area of science.

Progressive energy restriction (PER) yields similar fat-free mass and strength preservation as severe energy restriction (SER) in resistance-trained women, while potentially offering greater fat mass reduction and adherence due to its flexibility.

If you are a trained woman looking to lose fat while keeping your strength, try lowering your calories gradually over 8 weeks rather than cutting them drastically from day one. Start at 40 kcal per kg of fat-free mass and drop to 25 kcal/kg over two-week intervals. Keep protein high (~2.5g/kg) and maintain your resistance training. This approach is just as effective for preserving muscle and losing fat as severe restriction, but is easier to stick to.

Dual and triple receptor agonists (Tirzepatide, Survodutide, Retatrutide) show promise in MASH resolution, with some demonstrating superior efficacy to single GLP-1 agonists in weight loss and MASH resolution, though long-term hepatic outcomes are still being established.

Newer multi-agonist drugs like Tirzepatide (5-15mg weekly) show strong results in resolving MASH and improving fibrosis in Phase 2 trials, often matching or exceeding the efficacy of single GLP-1 agonists. Patients should discuss access and cost with their providers, as these are newer, expensive therapies with robust but still maturing long-term data.

Semaglutide produces greater weight loss than liraglutide but is associated with more intense gastrointestinal adverse effects, particularly nausea and vomiting.

If you are choosing between semaglutide and liraglutide for weight loss, expect semaglutide to deliver better results but with more intense stomach issues like nausea and vomiting. These side effects are usually mild or moderate and tend to decrease over time. If you have a sensitive stomach, liraglutide might be better tolerated, but you may lose less weight.

GLP-1 receptor agonists (liraglutide and exenatide) produce significant weight loss and BMI reduction in women with PCOS, alongside improvements in metabolic and cardiovascular risk markers.

For women with PCOS and obesity, GLP-1 agonists like liraglutide and exenatide are effective for weight loss and improving metabolic health. Treatment involves starting at a low dose to manage side effects like nausea, then titrating up to the therapeutic dose (1.8mg for Liraglutide, 10mcg BID for Exenatide) over several weeks. This should be combined with lifestyle changes.

GLP-1 receptor agonists improve reproductive outcomes in women with PCOS, including increased menstrual regularity and spontaneous pregnancy rates, by reducing androgen levels and improving insulin resistance.

If you have PCOS and are struggling with irregular periods or infertility, GLP-1 agonists may help regulate your cycle and increase your chances of natural pregnancy by lowering testosterone and improving insulin sensitivity. However, these medications should be stopped before trying to conceive, and their safety during pregnancy is still being studied.

GLP-1 receptor agonists improve cardiovascular risk markers in women with PCOS, including reductions in inflammatory markers (CRP) and improvements in endothelial function, although effects on lipid profiles are inconsistent.

GLP-1 agonists can improve your heart health by reducing inflammation and improving blood vessel function, which is important for PCOS patients. However, they may not consistently lower cholesterol levels, so monitoring other cardiovascular risk factors is also important.

GLP-1 receptor agonists (GLP-1RAs) reduce systemic inflammation and improve metabolic parameters in patients with psoriatic disease (PsD) and its comorbidities (obesity, T2DM, cardiovascular disease).

If you have psoriasis or psoriatic arthritis along with obesity or type 2 diabetes, GLP-1 receptor agonists (like semaglutide or liraglutide) can help manage both your metabolic health and inflammation. These drugs not only promote significant weight loss but also reduce key inflammatory markers (TNF, IL-6) linked to psoriatic disease severity. While they are primarily known for diabetes and weight management, emerging evidence suggests they may also improve joint and skin symptoms, especially in patients who are obese. Consult your rheumatologist to see if adding a GLP-1RA to your current treatment plan is appropriate.

Increasing dietary protein intake alone does not overcome anabolic resistance in T2D, but protein supplementation combined with resistance exercise may improve lean mass gains compared to exercise alone.

For T2D patients, drinking protein shakes alone won't build muscle. However, if you are doing resistance training, adding a protein drink (especially with leucine) alongside your workout can help you gain a bit more lean mass than exercise alone. Aim for adequate daily protein (1.2-1.6 g/kg) and consider post-workout supplementation.

Combining neuromuscular electrical stimulation (NMES) with high protein supplementation (HPRO) and physical therapy (PT) mitigates lower extremity muscle loss and restores positive nitrogen balance in critically ill, mechanically ventilated patients compared to standard care.

For critically ill patients who cannot actively exercise, combining high protein intake (approx 1.3g/kg/day) with twice-daily neuromuscular electrical stimulation (NMES) on the legs and physical therapy significantly reduces muscle loss compared to standard care. This multimodal approach helps maintain muscle mass and improves nitrogen balance, which is crucial for recovery in the ICU.

Resistance training significantly improves muscle strength and physical function in older adults with sarcopenia, but the magnitude of improvement often fails to exceed the Minimal Important Difference (MID) thresholds for clinical relevance.

For older adults with sarcopenia, resistance training is beneficial for strength but may not be enough to restore full functional independence on its own. To maximize benefits, aim for a high frequency (3 times/week) and a total weekly volume around 1220 MET-min/week for grip strength, or 600 MET-min/week for walking speed. However, manage expectations: these improvements might not be large enough to drastically change daily functional status without additional interventions.

Higher training frequency (3 times/week vs. 2 times/week) and specific resistance types (Constant for knee extension, Combined for gait speed) are key effect modifiers for optimizing resistance training outcomes in sarcopenia.

To maximize strength gains from resistance training, aim for 3 sessions per week rather than 2. If your goal is knee strength, constant resistance machines may be best. If your goal is walking speed, a mix of resistance types (combined) might be superior. Individualize your program based on these specific goals.

A structured group-based behavioral intervention utilizing social identity principles can effectively support weight management in adults with severe obesity (BMI ≥35 or ≥40 kg/m²) by leveraging shared social identity and social connectedness to drive behavioral change.

If you have severe obesity, joining a structured group program that focuses on building connections with other participants (not just learning diet tips) may be more effective for long-term weight loss than individual counseling. The PROGROUP protocol involves 15 sessions over 5 months, starting with weekly meetings and moving to fortnightly maintenance sessions, facilitated by a multidisciplinary team to ensure social support drives your behavioral changes.

High egg intake (up to 12 eggs/week) does not significantly increase cardiovascular risk, inflammatory biomarkers, or blood sugar levels in type 2 diabetic patients when part of a weight-loss diet.

You can likely include eggs in your diet. A study showed that eating up to 12 eggs a week did not worsen blood sugar or heart health markers in diabetics.

Exercise improves insulin sensitivity and reduces diabetes risk by enhancing microvascular endothelial function and capillary recruitment, independent of weight loss.

Start exercising regularly to improve your body's ability to use insulin. You don't need to lose weight for this to work; the exercise itself improves blood flow to your muscles, helping insulin get where it needs to go. This is the first recommended step for managing or preventing type 2 diabetes.

Lower recency (reliance on time-distant information rather than immediate outcomes) in decision-making predicts successful weight loss (≥5% reduction) in behavioral weight management interventions.

To succeed in a weight loss program, you need to train your brain to value long-term health outcomes over immediate gratification. This isn't just about willpower; it's about how you process information. If you find yourself making decisions based on how you feel right now (high recency), try to consciously engage in 'time-distant' thinking. Ask yourself what the long-term consequences of this choice are, rather than just the immediate pleasure. This cognitive shift is a stronger predictor of success than general intelligence or past dieting history.

Cluster sets (CS) elicit similar muscular hypertrophy to traditional sets (TS) when volume (sets/reps) and effort (RIR 0-1) are equated.

If you prefer cluster sets (pausing between reps/blocks), you can build muscle just as effectively as traditional sets, provided you match the total number of reps and train close to failure (0-1 reps in reserve). Don't worry about the total weight moved being lower in CS; focus on hitting your rep targets with high effort.

Exposure to educational Planetary Health Plate (PHP) signage in a university dining hall significantly reduces the rate at which patrons take meat dishes, but does not significantly reduce the total weight of meat consumed or the average serving size.

Educational signage alone may not reduce total meat consumption in a buffet setting. While it can discourage some people from taking meat entirely, it does not reduce portion sizes. To reduce total intake, interventions must address portion control or serving sizes directly, not just information provision.

Semaglutide administration (up to 1.0 mg/week) in obese heart failure patients significantly reduces BMI and improves functional capacity (NYHA class and 6-minute walk distance) compared to standard medical therapy alone.

For obese heart failure patients, adding semaglutide to standard care can significantly reduce weight and improve heart failure symptoms and walking distance. The medication is taken once weekly, starting at a low dose to minimize nausea, and titrated up over months. While not a cure, it offers a pharmacological option for weight management in this specific population where exercise may be limited by dyspnea.

Semaglutide treatment (1.7-2.4 mg weekly) in patients with hypothalamic obesity secondary to craniopharyngioma produces sustained, clinically significant weight loss (median 16%) and improves metabolic biomarkers (HbA1c, LDL) over 24 months.

For patients with hypothalamic obesity, semaglutide (1.7-2.4 mg weekly) is an effective long-term treatment for weight loss and metabolic health. It is crucial to maintain consistent dosing, as interruptions can lead to fat mass regain. Side effects are generally mild and manageable.

Semaglutide treatment significantly reduces emotional and uncontrolled eating scores in patients with hypothalamic obesity, leading to improved quality of life and social functioning.

Semaglutide not only helps with weight loss but also significantly reduces emotional and uncontrolled eating, leading to improved quality of life and social functioning. Patients report feeling more confident and less isolated.

Multi-modal anti-obesity medication (mmAOM) therapy yields significantly greater preoperative percent total body weight loss (%TBWL) than GLP-1 receptor agonist monotherapy or non-pharmacologic medically supervised weight loss in patients with BMI ≥ 70 kg/m².

If you have a BMI of 70 or higher and are preparing for weight loss surgery, combining multiple weight loss medications (mmAOM) under medical supervision leads to significantly more weight loss than using just one GLP-1 medication or lifestyle changes alone. This approach helps reduce surgical risks. Discuss with your doctor if a combination therapy is appropriate for your insurance coverage and health profile.